Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer’s disease patients

被引：0
作者：
Miyo K. Chatanaka
Ioannis Prassas
Eleftherios P. Diamandis
机构：
[1] University of Toronto,Department of Laboratory Medicine and Pathobiology
[2] University Health Network,Laboratory Medicine Program
[3] Lunenfeld-Tanenbaum Research Institute,undefined
[4] Mount Sinai Hospital,undefined
来源：
BMC Medicine | / 22卷
关键词：
Alzheimer’s disease; Biomarker; Non-invasive; SMOC1; Neuropentraxin; Diagnostic test; Reference range;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In this commentary, we address a paper published by Johnson et al. by assessing the robustness of their method to discover diagnostic biomarkers in Alzheimer’s disease (AD). In addition, we examine how these newly discovered and previously discovered biomarkers, can play a role in assisting patients with AD and those at risk for developing AD, with an emphasis on the translational hurdles that accompany such discoveries.
引用
收藏
相关论文
共 56 条
[1]  
Johnson ECB(2023)Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease Nat Med 29 1979-1988
[2]  
Bian S(2023)Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer’s disease Sci Transl Med 15 eabq5923-2292
[3]  
Haque RU(2018)Targeted mass spectrometry-based assays for relative quantification of 30 brain-related proteins and their clinical applications J Proteome Res 17 2282-20
[4]  
Carter EK(2016)Identification of brain-enriched proteins in the cerebrospinal fluid proteome by LC-MS/MS profiling and mining of the Human Protein Atlas Clin Proteomics 13 11-97.e7
[5]  
Watson CM(2018)Brain-related proteins as potential CSF biomarkers of Alzheimer’s disease: a targeted mass spectrometry approach J Proteomics 182 12-1881
[6]  
Gordon BA(2018)Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer’s disease progression F1000Res 7 1012-1268
[7]  
Sung YJ(2020)Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer’s disease Neurosci Lett 731 135078-903
[8]  
Yang C(2020)Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer’s disease: a 24-month follow-up study Neurobiol Aging 93 97.e1-undefined
[9]  
Norton J(2019)Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer’s disease Clin Chem Lab Med 57 1875-undefined
[10]  
Johnson M(2020)A multi-cancer detection test: focus on the positive predictive value Ann Oncol 31 1267-undefined
123456